Journal of Epidemiology

Longeveron Announces Phase 2 Clinical Trial in Japan to Test Safety and Efficacy of Lomecel-B on Aging Frailty Patients

Retrieved on: 
Tuesday, November 30, 2021

The overall prevalence of frailty amongst this demographic is estimated to be 7.9% [1]

Key Points: 
  • The overall prevalence of frailty amongst this demographic is estimated to be 7.9% [1]
    Lomecel-B has been evaluated in Phase 1 & 2 aging frailty clinical studies in the U.S.
  • A Phase 2 clinical trial is currently underway in babies with HLHS.
  • The Japanese Phase 2 study is a randomized, double-blind, placebo-controlled design approved by Japans Pharmaceuticals and Medical Devices Agency (PMDA).
  • Longeveron is currently sponsoring Phase 1 and 2 clinical trials in the following indications: Aging Frailty, Alzheimers disease, the Metabolic Syndrome, Acute Respiratory Distress Syndrome (ARDS), and hypoplastic left heart syndrome (HLHS).